Results 51 to 60 of about 3,063 (143)

From Adult to Adolescent: Alignment in Clinical Trials and Outcomes in Axial Spondyloarthritis

Arthritis Care &Research, EarlyView.
Spondyloarthritis (SpA) is a group of chronic inflammatory diseases encompassing axial and peripheral forms, with up to 20% of patients developing symptoms before age 16. Despite this substantial pediatric burden, treatment options for juvenile‐onset SpA (JSpA), particularly those with axial disease (axJSpA), remain limited.
Pamela F. Weiss, Judith A. Smith, Robert A. Colbert, Erin Treemarcki, Michael H. Weisman, Walter P. Maksymowych, Hermine I. Brunner, for the Childhood Arthritis and Rheumatology Research Alliance, Spondyloarthritis Research and Treatment Network, and Pediatric Rheumatology Collaborative Study Group Advisory Council   +9 more
wiley   +1 more source

Clinical outcomes of baricitinib in patients with systemic lupus erythematosus: Pooled analysis of SLE-BRAVE-I and SLE-BRAVE-II trials.

PLoS ONE
BackgroundBaricitinib is an oral selective inhibitor of Janus kinase 1/2 that has achieved clinically meaningful outcomes for systemic lupus erythematosus (SLE).
Juntao Yin, Yantao Hou, Chaoyang Wang, Changjiang Qin   +3 more
doaj   +1 more source

A review study of targeting of AAK1 and JAK1/2 using baricitinib in COVID-19 infected human cells

مجله كليه طب الكندي, 2020
     The outbreak of a current public health coronavirus 2019 disease is a causative agent of a serious acute respiratory syndrome and even death. COVID-19 has exposed to multi-suggested pharmaceutical agents to control this global disease. Baricitinib,
Abeer M Al-Humaidhi
doaj   +1 more source

Efficacy and safety of baricitinib in treatment of systemic lupus erythematosus: a systematic review and meta-analysis

BMC Rheumatology, 2023
Background SLE is an autoimmune disease marked by broad immunological dysregulation and multi-system inflammation. Baricitinib is one of the novel treatments for SLE.
Abdallah R. Allam, Mohamed Salah Alhateem, Abdelrahman Mohamed Mahmoud   +2 more
doaj   +1 more source

Real‐world effectiveness and safety of secukinumab in giant cell arteritis: an Italian multicentre cohort study

Arthritis Care &Research, Accepted Article.
Objective The objective of this study was to evaluate the real‐world effectiveness and safety of secukinumab in giant cell arteritis (GCA) patients. Methods This multicentre retrospective study included patients with GCA who received secukinumab at 14 Italian centres with at least 6 months of follow‐up.
Luca Iorio, Federica Davanzo, Caterina Ricordi, Milena Bond, Ruggiero Mascolo, Jacopo Mora, Alessandro Tomelleri, Angelo Fassio, Francesca Cuzzocrea, Sara Monti, Edoardo Conticini, Fabiola Atzeni, Paolo Delvino, Carlotta Nannini, Augusta Ortolan, Francesco Pollastri, Ester Vivaldelli, Chiara Marvisi, Paola Toniati, Antonio Brucato, Alessandra Milanesi, Francesca Regola, Enrico Tombetti, Lorenzo Dagna, Roberta Ramonda, Christian Dejaco, Luca Quartuccio, Carlo Salvarani, Roberto Padoan, The Italian Society of Rheumatology Vasculitis Study Group   +29 more
wiley   +1 more source

Baricitinib‐induced paradoxical psoriasis

, 2020
Although recent drugs including biological agents and small molecules targeting key inflammatory mediators have revolutionized the management of different chronic inflammatory diseases, these treatments lead to the development of psoriasis-like skin ...
J. Castagna, Prati, C., Gilliet, M., C. Conrad, M. Gilliet, J. Di Domizio, Castagna, J., Algros, M.P., F. Aubin, Di Domizio, J., M.P. Algros, D. Wendling, Aubin, F., C. Prati, Conrad, C., Wendling, D.   +15 more
core   +1 more source

Multi‐Technique Integration Identifies O‐GlcNAc Transferase in Fibroblast‐Like Synoviocytes as a Therapeutic Target for Rheumatoid Arthritis

Advanced Science, EarlyView.
AI‑guided single‑cell transcriptomics identifies OGT as a key regulator enriched in rheumatoid arthritis fibroblast‑like synoviocytes (RA‐FLSs). Inflammatory stimuli activate the OGT–SAP130 axis, which modulates the H3K27ac/H3K27me3 balance and epigenetically silences BTG2, promoting aggressive transformation of RA‑FLSs.
Duoli Xie, Jie Huang, Chunhao Cao, Zhenchao Tang, Xingchen Li, Jianmin Guo, Xinxin Chen, Fang Wang, Dongyi He, Jie Li, Yu Du, Bing He, Jianhua Yao, Aiping Lu, Chao Liang   +14 more
wiley   +1 more source

Accelerating Primary Screening of USP8 Inhibitors from Drug Repurposing Databases with Tree‐Based Machine Learning

Advanced Intelligent Discovery, EarlyView.
This study introduces a tree‐based machine learning approach to accelerate USP8 inhibitor discovery. The best‐performing model identified 100 high‐confidence repurposable compounds, half already approved or in clinical trials, and uncovered novel scaffolds not previously studied. These findings offer a solid foundation for rapid experimental follow‐up,
Yik Kwong Ng, Sharon Ai Er Lam, Wei Chun Lim, Hannah Hui Min Toh, Shi Jun Ang   +4 more
wiley   +1 more source

Baricitinib: therapeutic potential for moderate to severe atopic dermatitis [PDF]

, 2020
Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease mediated by multiple signals including janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. Current therapeutic armamentarium consists of a limited
Peris K., D'Urso D. F., Tambone S., Calabrese L., Malvaso D., Chiricozzi A., Guerriero C.   +6 more
core   +2 more sources

A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata

Journal of Health Economics and Outcomes Research
# Background Ritlecitinib, a JAK3/TEC family kinase inhibitor, and baricitinib, a JAK1/2 inhibitor, are approved for treating severe alopecia areata (AA).
Ashley S. Cha-Silva, Kate H. Zhang, Christopher N. Graham, Samantha K. Kurosky, Helen Tran, Ernest H. Law, Eingun J. Song   +6 more
doaj   +1 more source